| Type | MGI:General | Description | after embryonic exposure to 150 mg/kg cyclopamine (an SHH signaling inhibitor), approximately one third of cyclopamine-treated embryos show a more normal looking face, with improved midfacial development, although the MNPs remain distinct |
